TDGF1 Antikörper (AA 38-188)
-
- Target Alle TDGF1 Antikörper anzeigen
- TDGF1 (Teratocarcinoma-Derived Growth Factor 1 (TDGF1))
-
Bindungsspezifität
- AA 38-188
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser TDGF1 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Neutralization (Neut)
- Produktmerkmale
- Mouse anti human Cripto
- Immunogen
- AA 38-188
- Klon
- MM0203-6M17
- Isotyp
- IgG1
- Top Product
- Discover our top product TDGF1 Primärantikörper
-
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 1-188) antibody
TDGF1 Reaktivität: Human WB, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) antibodyTDGF1 Reaktivität: Human, Ratte, Maus IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 37-70), (N-Term) antibodyTDGF1 Reaktivität: Maus WB, FACS Wirt: Kaninchen Polyclonal RB51515 unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 18-48), (N-Term) antibodyTDGF1 Reaktivität: Human WB, IHC (p) Wirt: Kaninchen Polyclonal RB3957 unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (Internal Region) antibodyTDGF1 Reaktivität: Human, Ratte, Maus ELISA, WB, IHC, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 1-50) antibodyTDGF1 Reaktivität: Human, Maus WB, IF, FACS, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 35-188) antibodyTDGF1 Reaktivität: Human ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (AA 1-188) antibodyTDGF1 Reaktivität: Human WB Wirt: Maus Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (Internal Region) antibodyVerified TDGF1 Reaktivität: Human ELISA, IHC Wirt: Ziege Polyclonal unconjugated
anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) (N-Term) antibodyTDGF1 Reaktivität: Human WB, IHC (p), EIA Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- Optimal dilutions should be determined by each laboratory for each application.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- 200 µL of PBS, pH 7.4
- Konzentration
- 500 µg/mL
- Buffer
- Lyophilized from a solution containing PBS, pH 7.4
- Lagerung
- -20 °C
-
- Target
- TDGF1 (Teratocarcinoma-Derived Growth Factor 1 (TDGF1))
- Andere Bezeichnung
- Cripto (TDGF1 Produkte)
- Synonyme
- CR antikoerper, CRGF antikoerper, CRIPTO antikoerper, CR1 antikoerper, cripto antikoerper, cb85 antikoerper, tdgf1 antikoerper, wu:fe01d04 antikoerper, zgc:109829 antikoerper, Cripto-1 antikoerper, cr1 antikoerper, cr1a antikoerper, frl-1 antikoerper, frl1 antikoerper, xcr1 antikoerper, TDGF1 antikoerper, tdgf3 antikoerper, cripto-3 antikoerper, teratocarcinoma-derived growth factor 1 antikoerper, teratocarcinoma-derived growth factor 1, member 3 L homeolog antikoerper, teratocarcinoma-derived growth factor 1, member 1 antikoerper, TDGF1 antikoerper, Tdgf1 antikoerper, tdgf1 antikoerper, tdgf1.3.L antikoerper, tdgf1.1 antikoerper
- UniProt
- P13385
- Pathways
- EGFR Signaling Pathway
-
